Home2024September (Page 19)

Cardiol Therapeutics, a significant player in the world of biotech industry with a profound dedication to excellence in developing innovative heart medicines, recently announced the completion of their trailblazing MAvERIC Phase II study on Recurrent Pericarditis (RP). The results of this breakthrough investigation will be